146
Participants
Start Date
November 1, 2016
Primary Completion Date
January 22, 2025
Study Completion Date
January 22, 2025
RGX-104
Ipilimumab
Docetaxel
Pembrolizumab
Carboplatin
Pemetrexed
Columbia University Medical Center, New York
Thomas Jefferson University Hospital, Philadelphia
Fox Chase Cancer Center, Philadelphia
Maryland Oncology, Columbia
Virginia Cancer Specialists, PC, Fairfax
Florida Cancer Specialist, Lake Mary
Comprehensive Hematology Oncology, St. Petersburg
The Sarah Cannon Research Institute, Nashville
James Graham Brown Cancer Center, Louisville
Regions Hospital, Saint Paul
Ochsner Clinic Foundation, New Orleans
OU Health Stephenson Cancer Center, Oklahoma City
University of Colorado, Aurora
Rocky Mountain Cancer Centers, Denver
Sarah Cannon Research Institute, Denver
Arizona Oncology, Tucson
Quantum Santa Fe, Santa Fe
Cedars-Sinai Medical Center, Los Angeles
Oregon Health Sciences University, Portland
Dartmouth Hitchcock Medical, Lebanon
CINJ, New Brunswick
Lead Sponsor
Inspirna, Inc.
INDUSTRY